Literature DB >> 6626420

Mexiletine disposition: individual variation in response to urine acidification and alkalinisation.

B G Mitchell, J A Clements, A Pottage, L F Prescott.   

Abstract

The disposition of mexiletine has been studied in five subjects on two occasions with urine pH controlled at 5.0 and at 8.0. With acid urine total plasma clearance was similar in all subjects (462 to 497 ml min-1) and the plasma half-life ranged from 3.8 to 9.2 h (mean 6.7 h). With alkaline urine the total plasma clearance varied considerably (239 to 441 ml min-1); the mean half-life, 9.7 h, (range 7.6 to 12.7 h) was not significantly different from that in the acid urine study. Renal clearance fell greatly in every subject on alkalinisation of the urine. The total plasma clearance fell by a similar amount in two. In the remaining three the fall in total clearance was much smaller because of an increase in non-renal clearance. The reduction in total plasma clearance only just achieved statistical significance. The increase in predicted steady-state plasma mexiletine concentrations during infusion with change in urine pH from 5 to 8 varied between +5% and +95% (mean +39%). Changes in urine pH have a predictable effect upon renal clearance of mexiletine. However, disposition is changed in an unpredictable manner and inter-subject variation in distribution volume and non-renal clearance are important factors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6626420      PMCID: PMC1428000          DOI: 10.1111/j.1365-2125.1983.tb02162.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Variable pharmacokinetics of mexiletine.

Authors:  C M Kaye; M A Kiddie; P Turner
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

2.  Data point weighting in pharmacokinetic analysis: intravenous paracetamol in man.

Authors:  J A Clements; L F Prescott
Journal:  J Pharm Pharmacol       Date:  1976-09       Impact factor: 3.765

3.  Absorption, distribution and elimination of mexiletine.

Authors:  L F Prescott; A Pottage; J A Clements
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

4.  The effect of spontaneous changes in urinary pH on mexiletine plasma concentrations and excretion during chronic administration to healthy volunteers.

Authors:  A Johnston; C D Burgess; S J Warrington; J Wadsworth; N A Hamer
Journal:  Br J Clin Pharmacol       Date:  1979-10       Impact factor: 4.335

5.  [Effect of kidney, liver or heart insufficiency on blood mexiletine levels].

Authors:  J Nitsch; G Steinbeck; B Lüderitz
Journal:  Internist (Berl)       Date:  1982-05       Impact factor: 0.743

6.  Model-independent steady-state volume of distribution.

Authors:  A B Straughn
Journal:  J Pharm Sci       Date:  1982-05       Impact factor: 3.534

7.  Spectrophotofluorometric and gas-liquid chromatographic methods for the estimation of mexiletine (Kö 1173) in plasma and urine.

Authors:  J G Kelly; J Nimmo; R Rae; R G Shanks; L F Prescott
Journal:  J Pharm Pharmacol       Date:  1973-07       Impact factor: 3.765

8.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

9.  Pharmacokinetics of mexiletine in renal insufficiency.

Authors:  D El Allaf; L Henrard; L Crochelet; D Delapierre; J Carlier; A Dresse
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

10.  Kinetics and bioavailability of mexiletine in healthy subjects.

Authors:  V Häselbarth; J E Doevendans; M Wolf
Journal:  Clin Pharmacol Ther       Date:  1981-06       Impact factor: 6.875

View more
  7 in total

1.  [Treatment with mexiletine. Clinical and pharmacokinetic studies].

Authors:  H Breithaupt; A Schmidt
Journal:  Klin Wochenschr       Date:  1988-06-01

Review 2.  Clinical pharmacokinetics of mexiletine.

Authors:  L Labbé; J Turgeon
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 3.  Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Authors:  J P Monk; R N Brogden
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

4.  Kinetics of oral and intravenous mexiletine: lack of effect of cimetidine and ranitidine.

Authors:  N H Brockmeyer; H Breithaupt; W Ferdinand; M von Hattingberg; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  Poisoning due to class 1B antiarrhythmic drugs. Lignocaine, mexiletine and tocainide.

Authors:  C P Denaro; N L Benowitz
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

Review 6.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

Review 7.  Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.

Authors:  B Jarvis; A J Coukell
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.